DHB (1-Testosterone): Dry Gains, High Pain
Last updated: March 2026
Dihydroboldenone (DHB, 1-testosterone) is the 5α-reduced analog of boldenone — producing dry, quality lean muscle gains without aromatization. It is widely regarded as one of the most painful injectable steroids due to solubility issues. This reference covers its pharmacology, practical considerations, and harm-reduction data.
Community Research
(vs. Testosterone = 100)
No AI Required
📋 On this page
How DHB Works
DHB is the 5α-reduced form of boldenone (EQ), structurally analogous to how DHT relates to testosterone — but with notably different pharmacological properties than DHT itself.
Boldenone (Equipoise) is the parent compound; DHB is its 5α-reduced metabolite, also called dihydroboldenone or 1-testosterone (not the same as testosterone despite the name). The 1,2-double bond distinguishes it from regular 5α-dihydrotestosterone and confers resistance to 3α-hydroxysteroid dehydrogenase inactivation, maintaining receptor binding activity in muscle tissue.
DHB does not aromatize to estradiol. As a 5α-reduced compound it lacks the substrate for aromatase conversion. This produces a consistently dry aesthetic — no water retention, no estrogen-driven bloating — similar to primobolan, trenbolone, and winstrol. An aromatase inhibitor is not needed for estrogen management from DHB itself, though any co-administered testosterone will still aromatize normally.
DHB is notoriously difficult to keep in solution. At standard concentrations (100-150mg/mL), it tends to crash out of carrier oil especially at lower temperatures, forming microcrystals at the injection site that cause severe, prolonged pain (2-5 days). Mitigation strategies used in community practice: dilution with benzyl alcohol, MCT/GSO mix, warming the oil before injection, and lower concentrations (50-75mg/mL). Higher concentrations (200mg/mL+) are widely reported as near-unusable.
Unlike Anadrol, Superdrol, or Dianabol, DHB is not 17α-alkylated and is not oral. Its injectable form bypasses first-pass metabolism without requiring the hepatotoxic modification. This means standard 17α-AA liver toxicity is not a concern — though any AAS can still impact hepatic function via other mechanisms at high doses. Liver values typically remain closer to normal compared to oral steroids.
What the Evidence Shows
DHB has minimal formal clinical research. Pharmacological data comes from receptor binding studies; human outcome data is community-based (labeled).
Risks & Side Effects
Key Takeaways
- 5α-reduced form of boldenone — structural analog to DHT/testosterone relationship
- Does not aromatize — consistently dry gains, no AI needed for DHB estrogen management
- Not 17α-alkylated — much lower hepatotoxicity than oral steroids
- 200 anabolic rating — more potent than testosterone on paper
- Injectable at 200-400mg/week in community practice
- PIP is the defining practical challenge — concentration and formulation matter enormously
- Severe post-injection pain lasting days — limits practical utility for many users
- Very limited clinical research — safety profile largely anecdotal
- HPTA suppression still requires full PCT planning
- High-concentration formulations (150mg/mL+) are nearly universally painful
- Injection site abscesses possible if sterility is not maintained
🛒 Monitoring Supplies
Cardiovascular monitoring and bloodwork are the key harm-reduction practices for DHB research.
Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and harm-reduction purposes only. Dihydroboldenone (DHB / 1-testosterone) is a Schedule III controlled substance under the Anabolic Steroid Control Act in the United States. It has not been approved by the FDA for any medical use. Possession without a valid prescription is illegal. This content does not constitute medical advice. Always consult a licensed physician before using any anabolic agent.